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Abstract
Somatic mutations of DNMT3A gene have recently been reported in acute myeloid leukemia (AML) and myelodysplastic
syndrome (MDS). We examined the entire coding sequences of DNMT3A gene by high-resolution melting analysis and
sequencing in Chinese patients with myeloid malignancies. R882 mutations were found in 12/182 AML and in 4/51 MDS, but
not in either 79 chronic myeloid leukemia (CML), or 57 myeloproliferative neoplasms (MPNs), or 4 chronic monomyelocytic
leukemia. No other DNMT3A mutations were detected in all patients. R882 mutations were associated with old age and
more frequently present in monoblastic leukemia (M4 and M5, 7/52) compared to other subtypes (5/130). Furthermore, 14/
16 (86.6%) R882 mutations were observed in patients with normal karyotypes. The overall survival of mutated MDS patients
was shorter than those without mutation (median 9 and 25 months, respectively). We conclude that DNMT3A R882
mutations are recurrent molecular aberrations in AML and MDS, and may be an adverse prognostic event in MDS.
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Introduction
Tumorigenesis is known to be a multistep process, which is the
result of not only genetic alterations but also epigenetic changes
[1]. DNA methylation is a major form of epigenetic modification
and plays an essential role in development, differentiation,
genomic stability, X-inactivation, and imprinting by specific
regulation of gene expression. DNA methylation occurs by
covalent addition of a methyl group at the 59 carbon of the
cytosine ring. The transfer of methyl groups from S-adenosyl-l-
methionine to cytosine is a heritable process that is catalyzed by
several DNA methyltransferases (DNMTs) during cell replication.
There are at least three different DNMTs involved in cellular
DNA methylation: DNMT1, DNMT3A, and DNMT3B. It has
been documented that abnormal methylation is involved in the
development of many tumors [1]. All three DNMTs are
constitutively expressed at different levels in most human tissues.
Overexpression of DNMTs and its association with alterated DNA
methylation have been observed in tumors including leukemias
[2]. Recently, somatic mutations in DNMT3A gene have been
found in acute myeloid leukaemia (AML) with a frequency of
22.1% [3]. Recurrent DNMT3A muations have also been
identified in myelodysplastic syndrome (MDS) [4]. The ‘‘hotspots’’
mutation occurs at the amino acid position 882, resulting in the
replacement of arginine by histidine (R882H), cysteine (R882C),
serine (R882S), or phenylalanine (R882P). This work studied the
occurrence of DNMT3A mutations in Chinese AML and MDS
patients.
Materials and Methods
Patients’ samples and cell lines
This study was approved by the Scientific Committee of Jiangsu
Province Health Department. Bone marrow aspirates or periph-
eral blood samples of patients with various hematologic malig-
nancies were collected after informed consent given. The patients
included 182 AML, 51 MDS, 79 chronic myeloid leukemia (CML)
(60 at chronic phase, 4 at accelerated phase, 15 at blast crisis), 57
myeloproliferative neoplasms (MPNs) (22 polycythemia vera, 28
essential thrombocythemia, and 7 primary myelofibrosis) and 4
chronic monomyelocytic leukemia (CMML). These hematological
malignancies were diagnosed according to the French-American-
British Cooperative Group Criteria and the 2008 World Health
Organization proposal [5,6]. Bone marrow specimens obtained at
the time of complete hematologic remission from five AML
patients with DNMT3A mutations at initial diagnosis and
peripheral blood from 73 healthy individuals were used as control.
Seven human leukemic cell lines (HL-60, NB4, THP-1, SHI-1,
U937, HEL, and K562, all provided by Dr. Suning Chen, Jiangsu
Institute of Hematology, Jiangsu, China) were cultured in RPMI
1640 medium containing 10% fetal calf serum. All cell lines were
harvested during exponential growth.
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For DNMT3A mutational analysis, 25 pairs of primers were
diesigned to amplify the entire coding sequences of DNMT3A
(Genbank AF067972.2). DNA fragment spanning the codon
R882 was amplified by polymerase chain reaction (PCR) using
the following primers: 59- TTTGGTTTCCCAGTCCACTA-
TAC -39 (forward), and 59- CCAGCAGTCTCTGCCTC -39
(reverse). The size of PCR product was 67-bp. PCR was
performed in 25-mL volume in the presence of 16 PCR buffer
(Invitrogen, Merelbeke, Belgium), 0.2 mmol/L of each dNTP,
2.5 mmol/L of MgCl2,0 . 4mmol/L of both forward and reverse
primers, 0.8 mmol/L of oligonucleotide calibrators [7], 16
LCgreen Plus (Idaho Technology Inc. Salt Lake City, Utah),
1 U Taq polymerase (MBI Fermentas, Canada), and 50 ng
genomic DNA. PCR reactions were carried out on a 7300
Thermo cycler (Applied Biosystems, Foster City, CA, USA). The
temperature cycling protocol consisted of an initial denaturation
step at 95uC for 5 minutes, followed by 40 cycles of denaturation
at 94uC for 30 seconds, annealing at 59uC for 30 seconds, and an
extension at 72uC for 30 seconds. The primer sets and PCR
conditions for other DNA fragments of DNMT3A exons will be
provided on request.
High-resolution melting analysis (HRMA) was performed for
PCR products by the LightScanner
TM platform (Idaho Technol-
ogy Inc. Salt Lake City, Utah). Plates were heated in the
LightScanner from 55uCu pt o9 5 uC with a ramp rate of
0.10uC/s. The melting curve analysis was carried out using the
LightScanner software package with CALL-ITH software (Idaho
Technology Inc. Salt Lake City, Utah). Melting profiles were
calibrated by internal oligonucleotide controls, and then normal-
ized, grouped and displayed as fluorescence-versus-temperature
plots or subtractive difference plots (-df/dt vs T).
DNA sequencing
A separate PCR was carried out to generate a larger amplicon
spanning R882 (410 bp). PCR conditions were similar with that for
HRMA except for the primers which were: 59-TCTG-
GGTGGCACGGTCTT -39 (forward) and 59-CCTTGCT-
TAATGGGTGTA -39 (reverse). PCR products were directly
sequenced on both strands using an ABI 3730 automatic sequencer.
Figure 1. Results of a dilution series of DNMT3A R882H mutant in a background of wild-type DNA detected by HRMA. A: normalized
melting curves; B: normalized difference curves. HRMA identified mutated R882H with the maximal sensitivity of 2%.
doi:10.1371/journal.pone.0026906.g001
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maximal sensitivity of 10% was obtained. Arrow showed the mutation site.
doi:10.1371/journal.pone.0026906.g002
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Statistical analysis was performed using the SPSS 13.0 software
package (SPSS, Chicago, IL, USA). Pearson Chi-square analysis
and Fisher exact test were carried out to compare the difference of
categorical variables between patient groups. Mann-Whitney’s U-
test was carried out to compare the difference of continuous
variables between patient groups. Survival was analyzed according
to the Kaplan-Meier method. For all analyses, a P-value of less
than 0.05 (two-tailed) was considered statistically significant.
Results and Discussion
The sensitivity of HRMA was evaluated by detecting plasmid
DNA with different concentrations of R882H mutant diluted by
wild type (0%, 1%, 2%, 5%, 10%, 25%, 50%, and 100% mutant).
HRMA could easily distinguish R882H mutation with the
maximal sensitivity of 2% in a background of wild-type DNA
(Figure 1). However, Mutated R882H was identified at the
maximal sensitivity of 10% by direct DNA sequencing (Figure 2).
In the cohort of 372 patients, 16 cases were discovered to harbor
a heterozygous R882 mutation of DNMT3A, including R882H
(n=11), R882C (n=4), and R882P (n=1). The representative
melting curves and sequence chromatograms of three types of R882
mutations were shown on Figure 3 and 4. R882 mutation, positive
in the bone marrow samples from 5 AML patients at initial
diagnosis, disappeared after complete remission. Furthermore,
R882 mutation was not present in the healthy control. No R882
mutations were found in all seven leukemic cell lines.
Figure 3. Representative melting shapes of three R882 mutations and wild-type DNA. WT: wild-type. Three R882 mutations could be
easily distinguished according to their different melting paths.
doi:10.1371/journal.pone.0026906.g003
Figure 4. Sequences of the mutated DNMT3A R882. A: wild type sequence; B: R882H mutation; C: R882C mutation; D: R882P mutation.
Mutations are indicated with black arrows.
doi:10.1371/journal.pone.0026906.g004
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patients (Table 1). The basic clinical data of these patients were
listed in Table 2. There were three types of mutations, including
R882H (n=8, 66.7%), R882C (n=3, 25.0%), and R882P (n=1,
8.3%). No correlation was observed between R882 mutations and
gender or white blood cell (WBC) counts. AML patients with
DNMT3A R882 mutations were more prevalent at older age and
present with significantly higher median platelet counts at
diagnosis compared to those without mutations (Table 1).
Although median WBC counts were higher in AML patients with
R882 mutations than those without mutations, no statistical
difference was observed. It is noticed that one patient (case 3 in
Table 2) had a period of panctyopenia four months before the
diagnosis of AML and another patient (case 11 in Table 2) had a
Table 1. Distribution of DNMT3A R882 mutations in AML and MDS.
R882 mutation Wild-type P
AML 12 170
Sex, male/female 10/2 100/70 0.081
Median age at diagnosis, years (range) 60 (49–93) 42 (18–86) 0.002
Median WBC at diagnosis, 610
9/L (range) 74.8 (1.3–197.7) 15.9 (0.5–528) 0.166
Median hemoglobin at diagnosis, g/L (range) 76 (53–142) 74 (32–147) 0.361
Median platelets at diagnosis, 610
9/L (range) 59 (30–134) 34 (4–447) 0.016
FAB, no. 0.060
M1 1 21
M2 4 73
M3 0 24
M4 2 28
M5 5 17
M6 0 7
Karyotype classification 0.001
Favorable 0 51
Intermediate 12 86
Poor 0 19
No data 0 14
MDS 4 47
Sex, male/female 3/1 26/21 0.625
Median age at diagnosis, years (range) 70 (59–76) 52 (15–84) 0.107
Median WBC at diagnosis, 610
9/L (range) 2.8 (2.1–8.9) 3.1 (1.2–37.9) 0.986
Median hemoglobin at diagnosis, g/L (range) 64 (57–118) 63 (26–130) 0.547
Median platelets at diagnosis, 610
9/L (range) 58 (36–119) 66 (10–1176) 0.808
WHO, no. 0.446
5q- 0 4
RA/RARS 0 7
RCMD/RCMD-RS 1 20
RAEB-1 1 8
RAEB-2 2 8
Karyotype classification 0.481
Favorable 4 34
Intermidiate 0 7
Poor 0 4
No data 0 2
IPSS 0.206
Low 0 6
Int-1 2 31
Int-2 2 5
High 0 5
WBC indicates white blood cell count at diagnosis; IPSS, International Prognostic Scoring System; WHO, World Health Organization; FAB, French-American-British
classification; RA, refractory anemia; RARS, refractory anemia with ringed sideroblasts; RCMD, refractory cytopenia with multilineage dysplasia; RCMD-RS, refractory
cytopenia with multilineage dysplasia with ringed sideroblasts; RAEB, refractory anemia with excess of blasts;
doi:10.1371/journal.pone.0026906.t001
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AML. Significant dysplastic changes were identified in bone
marrow of these two cases, such as megaloblastoid changes,
multinuclear erythroid precursors, and micromegakaryocytes.
Thus, AML derived from MDS might be considered in these
two patients. R882 mutations were also identified in two MDS-
derived AML [8], however, it was not determined whether the
mutations were present in bone marrow cells at the MDS stage
[8].
Furthermore, DNMT3A R882 mutations were found more
frequently among monoblastic leukemia (M4 and M5, 7 of 52,
13.4%) compared to non-monoblastic leukemia (M1, M2, M3 and
M6, 5 of 130, 3.8%) (P=0.041). This result further confirmed the
specificity of DNMT3A R882 mutations in monocytic lineage
[3,9].
In a total of 168 patients with cytogenetic data, all 12 DNMT3A
R882 mutations were observed in patients with intermediate-risk
karyotype (Table 1), mainly in patients with normal karyotypes (10
of 12 mutations, 83.3%). Two cytogenetically abnormal patients
harbored monosomy 17 and trisomy 21, respectively. Among the
patients with normal karyotypes, 13.2% (10 of 76) cases showed
R882 mutation, significantly higher than 2.2% (2 of 92) in those
with chromosomal abnormalities (P=0.007). No R882 mutation
was seen in patients with t(8;21), t(15;17), and other recurrent
chromosomal abnormalities, such as translocations involving
chromosome 11q23 and deletions involving chromosome 5 or 7.
4 (7.8%) heterozygous DNMT3A R882 mutations were also
identified in MDS, including 3 R882H and 1 R882C mutations.
The difference of age and hematologic parameters was not seen
between patients with and without mutations. However, all 4
patients were identified with normal karyotype and were classified
in intermediate-risk group according to IPSS classification. To
investigate the prognostic impact of DNMT3A mutations in MDS,
40 cases with follow-up data were considered for survival analysis.
The median follow-up of these patients was 23 months. The
overall survival (OS) of MDS patients with DNMT3A mutation
(median 9 months, 95% confidence interval 3–15 months) was
shorter than those without mutation (median 25 months, 95%
confidence interval 12–38 months) (P=0.047, Figure 5). A recent
study also identified 13 DNMT3A mutations in 12/150 (8.0%)
MDS patients [4]. R882 mutations were found in only 4 cases.
Correlation was not found between DNMT3A mutations and FAB
subtypes, karyotypes, or IPSS subgroups, suggesting that DNMT3A
mutation is an early genetic event in MDS. However, DNMT3A
mutations were shown to contribute to a worse overall survival [4].
An association of DNMT3A mutations with poor prognosis was
also observed in AML-M5 patients [9].
It should be noted that DNMT3A mutations in other nucleotide
sites were not found in our AML and MDS patients. Two groups
Table 2. The clinical and hematopoietic parameters of 16 patients with DNMT3A R882 mutations.
ID Sex/Age (years) Diagnosis
WBC
(610
9/L)
Haemoglobin
(g/L)
Platelet
(610
9/L) Karyotype DNMT3A mutation
1 M/49 AML-M2 2.7 59 47 N R882H
2 F/57 AML-M5 76.1 73 49 N R882C
3 M/60 AML-M2 1.3 60 65 N R882H
4 M/56 AML-M5 154.1 78 35 N R882H
5 F/70 AML-M5 135.4 65 77 N R882H
6 M/93 AML-M5 197.7 110 69 217 R882C
7 M/67 AML-M4 107.0 53 118 N R882H
8 M/63 AML-M1 88.3 104 30 +21 R882P
9 M/61 AML-M4 37.7 105 119 N R882H
10 M/54 AML-M2 10.7 90 40 N R882H
11 M/70 AML-M5 1.6 142 79 N R882H
12 M/54 AML-M2 73.4 68 134 N R882C
13 F/76 RAEB-2 2.8 65 47 N R882H
14 M/59 RCMD 8.9 62 70 N R882H
15 M/63 RAEB-2 2.7 118 119 N R882C
16 M/76 RAEB-1 2.1 57 36 N R882H
doi:10.1371/journal.pone.0026906.t002
Figure 5. Overall survival of MDS patients divided according to
DNMT3A mutation status at diagnosis.
doi:10.1371/journal.pone.0026906.g005
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MDS (40.3% and 69.2%, respecitively) [3,4]. However, Yan et al
observed only 13.0% (3/23) non-R882 mutations in Chinese
AML-M5 patients [9]. No DNMT3A mutations were detected in
pediatric AML by Ho et al [10]. These studies indicate that the
DNMT3A mutagenesis may differ within different races and be
associated with patient’s age.
Three recent studies have identified DNMT3A mutations in
6.7% PV, 4.4%–15% MF (including PMF and post-ET/PV MF)
and 0%–3.8% CMML [11–13]. No DNMT3A mutations were
found in all of our MPN and CMML patients. However, the
sample size was so small, more cases should be studied to
determine the exact frequency of DNMT3A mutations in Chinese
MPNs and CMML.
The catalytic activity relies on the methyltransferase (MTase)
domain of DNMT3A protein, which contains ten blocks of
conserved amino acid motifs [14,15]. The R882 residue, located in
front of motif X [15,16], is considered to participate in the
homodimerization and activation of the protein [17]. Mutations at
R882 residue inhibit both DNA binding and catalytic activity
[8,14]. Overexpression of DNMT3A has been reported in various
malignancies including AML [2]. Two recent studies have
revealed that depletion of DNMT3A inhibits tumor cell prolifer-
ation and metastasis [17,18]. Moreover, DNMT inhibitors such as
5-aza-29-deoxycytidine induce cancer cell apoptosis through the
covalent binding to DNMT3A and DNMT3B [19]. All of these
findings suggest that DNMT3A functions as an oncogene. It seems
that R882 mutations act in a dominant-negative fashion to reduce
the MTase activity of the enzyme. However, the absence of global
changes in DNA methylation in DNMT3A-mutated AML
indicates that there are other molecular mechanisms contributing
to leukemogenesis besides abnormal DNA methylation. More
works are required to determine the functional consequences of
R882 mutations and the underlying mechanisms.
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